KARPAS 1718

08072401, human spleen (lymphoma), Single round to polymorphic cells growing in suspension

• 分類程式碼代碼: 41106514

屬性

• 產品名稱: KARPAS 1718, NOTE: Both the cell line and DNA from the cell line may be available for this product. Please choose -1VL or VIAL for cells, or -DNA-5UG for DNA., 08072401
• 生物源: human spleen (lymphoma)
• 包裝: tube of 5 μg 08072401-DNA-5UG; pkg of vial of cells 08072401-1VL
• 增長模式: Suspension
• 染色體組型: Not specified
• 形態學: Single round to polymorphic cells growing in suspension
• 產品: Not specified
• 受體: Not specified
• 技術: cell culture | mammalian: suitable
• 相關疾病: cancer
• 運輸包裝: dry ice
• 儲存溫度: −196°C

描述

細胞系來源

Human splenic lymphoma

細胞系描述

KARPAS 1718 is derived from the peripheral blood of a patient diagnosed with transformed splenic lymphoma with villous lymphocytes

應用

Oncology research

DNA分析

STR-PCR Data: Amelogenin: X,Y
CSF1PO: 11,13
D13S317: 8,13
D16S539: 11,13
D5S818: 11,12
D7S820: 8
THO1: 6
TPOX: 8,11
vWA: 14

培養基

RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS)

例行更新培養

Maintain cultures between 3-9 x 10⁵ cells/ml; 5% CO₂; 37°C. Thaw ampoule and perform a cell count, spin out the DMSO and resuspend in an appropriate volume of media to give a cell concentration of 4-5 x 10⁵ cells/ml. Viability may be poor on resuscitation and may decrease further within the first 48 hours, the culture may appear non-viable at this time. Clusters of cells will eventually appear but this could take 1-2 weeks, during this time large media changes are not recommended. It may take 2-3 weeks for vigorous growth to be established. At subculture perform a cell count and maintain cultures between 3-9 x 105 cells/ml, 5% CO₂, 37°c. For cryopreservation of KARPAS 1718, freeze at approximately 2 x 107 cells/ml in 90% FBS + 10% DMSO.

其他說明

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

免責聲明

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.